Confidence In Network Meta Analysis - CINeMA 2.0.0 - Project: HFpEF network meta-analysis

Heterogeneity

Define clinically important size of effect: Odds ratio | 1 |

*Relative effect estimates below **1.000** and above **1.000** are considered clinically important.*
Importance of heterogeneity depends on the variability of effects in relation to a clinically important size of effect

The estimated value of between-study variance for the network meta-analysis is **0.000**

Comparison	ACEI:ARB
Evidence: mixed	
NMA estimate:	0.831
95% intervals for NMA estimate	
Confidence interval:	(0.433,1.594)
Prediction interval:	(0.353,1.952)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison	ACEI:Placebo
Evidence: mixed	
NMA estimate:	0.845
95% intervals for NMA estimate	
Confidence interval:	(0.448,1.595)
Prediction interval:	(0.368,1.944)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison	ARB:ARNI
Evidence: mixed	
NMA estimate:	1.036
95% intervals for NMA estimate	
Confidence interval:	(0.882,1.217)
Prediction interval:	(0.839,1.279)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison	ARB:Placebo
Evidence: mixed	
NMA estimate:	1.018
95% intervals for NMA estimate	
Confidence interval:	(0.877,1.180)
Prediction interval:	(0.837,1.236)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison Beta blockers:Placebo
Evidence: mixed

NMA estimate: 0.588
95% intervals for NMA estimate
Confidence interval: (0.363,0.953)
Prediction interval: (0.312,1.108)

*Prediction interval extends into clinically important effects in **both** directions*

Heterogeneity judgment

| Major concerns ▼ |

Comparison   Digoxin:Placebo
Evidence: mixed

NMA estimate: 0.999
95% intervals for NMA estimate
Confidence interval: (0.744,1.342)
Prediction interval: (0.679,1.471)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment

| No concerns ▼ |

Comparison   MRA:Placebo
Evidence: mixed

NMA estimate: 0.910
95% intervals for NMA estimate
Confidence interval: (0.756,1.096)
Prediction interval: (0.714,1.161)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment

| No concerns ▼ |

Comparison   Placebo:Sildenafil
Evidence: mixed

NMA estimate: 0.153
95% intervals for NMA estimate
Confidence interval: (0.008,2.989)
Prediction interval: (0.003,7.552)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment

| No concerns ▼ |

Comparison
Evidence: Placebo:Vericiguat 10mg
mixed

NMA estimate: 0.452
95% intervals for NMA estimate
Confidence interval: (0.181,1.127)
Prediction interval: (0.136,1.499)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment

| No concerns ▼ |

Comparison
Evidence: Placebo:Vericiguat 15mg
mixed

NMA estimate: 0.697
95% intervals for NMA estimate
Confidence interval: (0.261,1.860)
Prediction interval: (0.192,2.526)

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment

| No concerns ▼ |

Comparison
Vericiguat 10mg:Vericiguat 15mg
Evidence: mixed

NMA estimate: **1.542**
95% intervals for NMA estimate
Confidence interval: **(0.680,3.499)**
Prediction interval: **(0.527,4.516)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:ARNI
Evidence: indirect

NMA estimate: **0.861**
95% intervals for NMA estimate
Confidence interval: **(0.440,1.684)**
Prediction interval: **(0.357,2.075)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:Beta blockers
Evidence: indirect

NMA estimate: **1.437**
95% intervals for NMA estimate
Confidence interval: **(0.647,3.193)**
Prediction interval: **(0.505,4.094)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:Digoxin
Evidence: indirect

NMA estimate: **0.846**
95% intervals for NMA estimate
Confidence interval: **(0.420,1.703)**
Prediction interval: **(0.338,2.118)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:MRA
Evidence: indirect

NMA estimate: **0.929**
95% intervals for NMA estimate
Confidence interval: **(0.479,1.799)**
Prediction interval: **(0.390,2.211)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:Sildenafil
Evidence: indirect

NMA estimate: **0.129**
95% intervals for NMA estimate
Confidence interval: **(0.006,2.701)**
Prediction interval: **(0.002,6.969)**

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:Vericiguat 10mg
Evidence: indirect

NMA estimate: 0.382
95% intervals for NMA estimate
Confidence interval: (0.126,1.163)
Prediction interval: (0.089,1.645)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ACEI:Vericiguat 15mg
Evidence: indirect

NMA estimate: 0.589
95% intervals for NMA estimate
Confidence interval: (0.183,1.897)
Prediction interval: (0.127,2.730)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ARB:Beta blockers
Evidence: indirect

NMA estimate: 1.731
95% intervals for NMA estimate
Confidence interval: (1.044,2.869)
Prediction interval: (0.892,3.359)

Prediction interval extends into clinically important effects in **both** *directions*

Heterogeneity judgment
Major concerns   ▼

Comparison   ARB:Digoxin
Evidence: indirect

NMA estimate: 1.018
95% intervals for NMA estimate
Confidence interval: (0.732,1.416)
Prediction interval: (0.661,1.570)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ARB:MRA
Evidence: indirect

NMA estimate: 1.118
95% intervals for NMA estimate
Confidence interval: (0.882,1.418)
Prediction interval: (0.819,1.527)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ARB:Sildenafil
Evidence: indirect

NMA estimate: 0.155
95% intervals for NMA estimate
Confidence interval: (0.008,3.052)
Prediction interval: (0.003,7.721)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment
No concerns   ▼

Comparison   ARB:Vericiguat 10mg
Evidence: indirect

NMA estimate:	0.460

95% intervals for NMA estimate

Confidence interval:	(0.182,1.161)
Prediction interval:	(0.137,1.549)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison   ARB:Vericiguat 15mg
Evidence: indirect

NMA estimate:	0.709

95% intervals for NMA estimate

Confidence interval:	(0.263,1.914)
Prediction interval:	(0.193,2.608)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison   ARNI:Beta blockers
Evidence: indirect

NMA estimate:	1.670

95% intervals for NMA estimate

Confidence interval:	(0.983,2.840)
Prediction interval:	(0.833,3.350)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison   ARNI:Digoxin
Evidence: indirect

NMA estimate:	0.983

95% intervals for NMA estimate

Confidence interval:	(0.681,1.419)
Prediction interval:	(0.607,1.591)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison   ARNI:MRA
Evidence: indirect

NMA estimate:	1.079

95% intervals for NMA estimate

Confidence interval:	(0.810,1.438)
Prediction interval:	(0.741,1.572)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison   ARNI:Placebo
Evidence: indirect

NMA estimate:	0.982

95% intervals for NMA estimate

Confidence interval:	(0.789,1.223)
Prediction interval:	(0.737,1.309)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

No concerns ▼

Comparison　　　　ARNI:Sildenafil
Evidence: indirect

NMA estimate:　　　　　　　0.150
95% intervals for NMA estimate
Confidence interval:　　(0.008,2.959)
Prediction interval:　　(0.003,7.495)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison　ARNI:Vericiguat 10mg
Evidence: indirect

NMA estimate:　　　　　　　0.444
95% intervals for NMA estimate
Confidence interval:　　(0.173,1.136)
Prediction interval:　　(0.129,1.523)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison　ARNI:Vericiguat 15mg
Evidence: indirect

NMA estimate:　　　　　　　0.685
95% intervals for NMA estimate
Confidence interval:　　(0.251,1.872)
Prediction interval:　　(0.183,2.560)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison　Beta blockers:Digoxin
Evidence: indirect

NMA estimate:　　　　　　　0.588
95% intervals for NMA estimate
Confidence interval:　　(0.334,1.036)
Prediction interval:　　(0.280,1.236)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison　　　Beta blockers:MRA
Evidence: indirect

NMA estimate:　　　　　　　0.646
95% intervals for NMA estimate
Confidence interval:　　(0.385,1.084)
Prediction interval:　　(0.328,1.274)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison
Evidence:　Beta blockers:Sildenafil
indirect

NMA estimate:　　　　　　　0.090
95% intervals for NMA estimate
Confidence interval:　　(0.004,1.827)
Prediction interval:　　(0.002,4.673)

Confidence and prediction intervals **agree** *in relation to clinically important effect*

Heterogeneity judgment

| No concerns　　　▼ |

Comparison
Beta blockers:Vericiguat 10mg
Evidence: indirect

NMA estimate: **0.266**
95% intervals for NMA estimate
Confidence interval: **(0.095,0.747)**
Prediction interval: **(0.068,1.031)**

*Prediction interval extends into clinically important effects in **both** directions*

Heterogeneity judgment
| Major concerns ▼ |

Comparison
Beta blockers:Vericiguat 15mg
Evidence: indirect

NMA estimate: **0.410**
95% intervals for NMA estimate
Confidence interval: **(0.137,1.224)**
Prediction interval: **(0.098,1.721)**

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison   Digoxin:MRA
Evidence: indirect

NMA estimate: **1.098**
95% intervals for NMA estimate
Confidence interval: **(0.775,1.555)**
Prediction interval: **(0.695,1.733)**

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison   Digoxin:Sildenafil
Evidence: indirect

NMA estimate: **0.152**
95% intervals for NMA estimate
Confidence interval: **(0.008,3.030)**
Prediction interval: **(0.003,7.691)**

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison
Evidence: Digoxin:Vericiguat 10mg indirect

NMA estimate: **0.452**
95% intervals for NMA estimate
Confidence interval: **(0.173,1.180)**
Prediction interval: **(0.128,1.592)**

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison
Evidence: Digoxin:Vericiguat 15mg indirect

NMA estimate: **0.697**
95% intervals for NMA estimate
Confidence interval: **(0.250,1.941)**
Prediction interval: **(0.182,2.671)**

*Confidence and prediction intervals **agree** in relation to clinically important effect*

Heterogeneity judgment
| No concerns ▼ |

Comparison   MRA:Sildenafil
Evidence: indirect

NMA estimate: 0.139
95% intervals for NMA estimate
Confidence interval: (0.007,2.736)
Prediction interval: (0.003,6.925)

Confidence and prediction intervals
agree *in relation to clinically*
important effect

Heterogeneity judgment

No concerns   ▼

Comparison   MRA:Vericiguat 10mg
Evidence: indirect

NMA estimate: 0.411
95% intervals for NMA estimate
Confidence interval: (0.162,1.046)
Prediction interval: (0.121,1.398)

Confidence and prediction intervals
agree *in relation to clinically*
important effect

Heterogeneity judgment

No concerns   ▼

Comparison   MRA:Vericiguat 15mg
Evidence: indirect

NMA estimate: 0.635
95% intervals for NMA estimate
Confidence interval: (0.234,1.723)
Prediction interval: (0.171,2.352)

Confidence and prediction intervals
agree *in relation to clinically*
important effect

Heterogeneity judgment

No concerns   ▼

Comparison
          Sildenafil:Vericiguat 10mg
Evidence: indirect

NMA estimate: 2.964
95% intervals for NMA estimate
Confidence interval: (0.132,66.620)
Prediction interval: (0.050,175.686)

Confidence and prediction intervals
agree *in relation to clinically*
important effect

Heterogeneity judgment

No concerns   ▼

Comparison
          Sildenafil:Vericiguat 15mg
Evidence: indirect

NMA estimate: 4.572
95% intervals for NMA estimate
Confidence interval: (0.199,104.878)
Prediction interval: (0.075,278.356)

Confidence and prediction intervals
agree *in relation to clinically*
important effect

Heterogeneity judgment

No concerns   ▼